This Blog AMICOR is a communication instrument of a group of friends primarily interested in health promotion, with a focus on cardiovascular diseases prevention.
To contact send a message to
Summary: Researchers announce a new study that aims to identify new biomarkers that can be detected during the earliest stages of Alzheimer’s disease.
Source: University of Oxford.
A new multimillion pound study, which will see the most thorough and rigorous series of tests to detect Alzheimer’s disease ever performed on volunteers, is announced today (Monday 22 August). The Deep and Frequent Phenotyping study is funded by the National Institute of Health Research and the MRC and hopes to dramatically improve the success rate of clinical trials for treatments in Alzheimer’s disease.
This landmark £6.9million research project has been designed to identify measurable characteristics, known as biomarkers, which can detect the occurrence of Alzheimer’s disease very early on in the progression of the disease – when a person may have no obvious symptoms./.../
Between 2002 and 2012, 99% of clinical trials into treatments for Alzheimer’s disease failed.
The tests will include wearable devices that will give researchers detailed information on people’s movement and gait, and sophisticated retinal imaging that will look at subtle changes affecting a person’s central and peripheral vision.
An estimated 46.8m people worldwide were living with dementia in 2015, and with an ageing population in most developed countries, predictions suggest this number may double by 2050. Currently, there is no known cure for the disease, and few treatments which are available treat symptoms of the disease, rather than slow or stop its progression.